20.03.2017 • News

BP may Sell Forties Pipeline to Ineos

(c) Chrispo/Shutterstock
(c) Chrispo/Shutterstock

British oil and petrochemicals major BP and Swiss-based olefins and polyolefins producer Ineos have confirmed they are in talks about Ineos taking over the 100-mile-long Forties Pipeline System, which carries around 40% of the UK’s oil production and eventually supplies Ineos’ refinery at Grangemouth, Scotland.

Talks are believed to have begun a year ago but stalled on pricing issues. Some reports said the price was likely to be in the £200 million range.

The pipeline was originally built to transport 1 million bbl of oil from the Forties field – which was discovered in 1970 – to the Grangemouth complex, formerly owned by BP. The oil group sold its Forties interests to Apache in 2003 and the Grangemouth refinery and chemical complex to Ineos in 2005.

Grangemouth is now Ineos’ largest manufacturing site by volume of products, and home to Scotland’s only crude oil refinery, which produces the bulk of the country’s fuels.

Use of the pipeline has declined steadily as North Sea oil production has dwindled, and the pipeline's average daily throughput is currently put at around 450,000 bbl.

The trade union Unite said it wants to have a word with BP about the proposed sale. Referring to the 2013 conflict between Unite and Ineos’ management at Grangemouth, the union’s Scottish secretary, Pat Rafferty, said: "Our members at BP will have major concerns about the possibility of becoming employees of Ineos, a company with a clear history of attacking our members' pensions, as well as their terms and conditions, in order to maximize profit.”

"If a sale does go ahead,” he said, “we will fight to protect our members in every way we can, and Ineos should work with us to allay their fears." About 300 BP employees currently operate and support the pipeline system.

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.